Regenesis

Executive Summary

Regenesis is a US-based medical device company focused on non-invasive, energy-based therapies for pain management and tissue repair. Its flagship product, Reprieve, is an electromagnetic shortwave diathermy device cleared by the FDA for home use to treat chronic musculoskeletal pain. The company's non-pharmacological approach addresses the growing demand for opioid-sparing pain relief options, positioning it well in the expanding regenerative medicine market. While Regenesis has a commercial product, its growth depends on broadening indications, securing reimbursement, and expanding market adoption. The company's private status and lack of disclosed funding or valuation suggest a lean operation, but its existing clearance provides a foundation for scale. With a differentiated product in a crowded pain management space, Regenesis could capture niche segments, though competition from other energy-based devices and alternative therapies remains a risk.

Upcoming Catalysts (preview)

• Q3 2026FDA clearance expansion for Reprieve to treat post-surgical pain or neuropathic pain60% success
• Q4 2026Publication of clinical trial results demonstrating efficacy in chronic low back pain vs. standard care50% success
• TBDStrategic partnership with a national distributor to expand home-use device reach40% success